Although the higher prevalence of insulin abnormalities and insulin resistance are reported in patients with AD [37, 38], how AD genetic risk impacts the clinical profiles for diabetic patients, leading to reduced or delayed initialization of insulin therapy determined by their physicians, is unclear. This evidence concerns the gene INS and Insulin resistance.